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Blocking angiogenesis is an attractive strategy to in-
hibit tumor growth, invasion, and metastasis. We de-
scribe here the structure and the biological action of a
new cyclic peptide derived from vascular endothelial
growth factor (VEGF). This 17-amino acid molecule des-
ignated cyclopeptidic vascular endothelial growth in-
hibitor (cyclo-VEGI, CBO-P11) encompasses residues
79–93 of VEGF which are involved in the interaction
with VEGF receptor-2. In aqueous solution, cyclo-VEGI
presents a propensity to adopt a helix conformation that
was largely unexpected because only -sheet structures
or random coil conformations have been observed for
macrocyclic peptides. Cyclo-VEGI inhibits binding of io-
dinated VEGF165 to endothelial cells, endothelial cells
proliferation, migration, and signaling induced by
VEGF165. This peptide also exhibits anti-angiogenic ac-
tivity in vivo on the differentiated chicken chorioallan-
toic membrane. Furthermore, cyclo-VEGI significantly
blocks the growth of established intracranial glioma in
nude and syngeneic mice and improves survival without
side effects. Taken together, these results suggest that
cyclo-VEGI is an attractive candidate for the develop-
ment of novel angiogenesis inhibitor molecules useful
for the treatment of cancer and other angiogenesis-re-
lated diseases.
Angiogenesis takes place during embryonic development and
in the adult during wound healing and the female ovulatory
cycle. In pathological states, angiogenesis is observed during
solid tumor growth and metastasis, diabetic retinopathy, and
chronic inflammatory disorders. A number of angiogenic regu-
lators such as vascular endothelial growth factors (VEGFs),1
fibroblast growth factors (FGFs), and angiopoietins have been
identified (1–4).
VEGFs are endothelial cell mitogens in vitro and also stim-
ulate angiogenesis in vivo (2, 5, 6). VEGF exerts its biological
effects through high affinity binding to two tyrosine kinase
receptors, VEGFR1 (Flt-1) and VEGFR2 (kinase domain recep-
tor), which are expressed in most vascular endothelial cells
(6–8). VEGF is expressed in a large number of human tumor
types (9, 10). Clinical studies have documented the importance
of VEGF in human cancers. As an example, VEGF is increased
in the plasma of cancer patients and is correlated with response
to chemotherapy (11, 12). In growing tumors, VEGF expression
is up-regulated by hypoxia, growth factors, and oncogenes
(6, 13).
Antagonizing VEGF has shown to inhibit tumor develop-
ment in vivo. Different strategies have been designed to inhibit
VEGF function. These include monoclonal neutralizing anti-
bodies (14), dominant-negative mutants of the VEGF recep-
tor-2 (VEGFR2) (15), antisense oligonucleotides (16), anti-
VEGFR2 antibodies (17), blockers of VEGFR2 tyrosine
phosphorylation (18), VEGF-toxin conjugates (19), antagonistic
VEGF mutants (20), peptides that interfere with VEGF/
VEGFR interactions (21–25), and decoy-soluble receptors (26).
Relevant regions of VEGF important for its binding on
VEGFR2 and VEGFR1 have been investigated by structural
and mutagenesis studies (27–29). Some of the residues impor-
tant for the interaction between VEGF and kinase domain
receptor are clustered within region 79–93 of VEGF which
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forms a -hairpin, Arg82, Lys84, and His86 being key residues
(27). Based on these structural and mutagenesis studies, a
number of cyclic and linear peptides have been synthesized.
One of the most potent compound was the cyclic peptide CBO-
P11 (D-Phe-Pro79–93) designated herein cyclopeptidic vascular
endothelial growth inhibitor (cyclo-VEGI).2 In the present re-
port, we determined the structural features of this peptide and
characterized its biological properties. We show that this pep-
tide adopts an unexpected three-dimensional structure and is
able to inhibit critical steps of angiogenesis. Moreover, this
peptide inhibits the growth of both established human in-
tracranial and syngeneic glioma in mice.
EXPERIMENTAL PROCEDURES
Structural Analysis of Cyclo-VEGI (CBO-P11)
NMR Spectroscopy—NMR samples were prepared at a 2 mM peptide
concentration in water or in mixtures of TFE-d3/water containing 10%
D2O. All NMR spectra were recorded on Bruker Avance spectrometers
operating at a 1H frequency of 500 MHz and were processed with the
Bruker XWINNMR program. One-dimensional spectra were acquired
over 16 K data points using a spectral width of 5000 Hz and a reference
to internal sodium 3-trimethylsilyl-(2,2,3,3-2H4)propionate at 0 ppm.
Solvent suppression was achieved by presaturation during the relax-
ation delay (1.5 s) or with a WATERGATE sequence using pulsed field
gradients (30). Proton assignments were obtained at 288 and 298 K
from the analysis of TOCSY (20- and 80-ms isotropic mixing times) and
NOESY (150-, 200-, or 300-ms mixing times) spectra (31, 32). Typically,
two-dimensional data were collected with 400–600 t1 increments and
2048 data points in t2, over a spectral width of 6000 Hz in both dimen-
sions. Prior to Fourier transformation in t2 and t1, the time domain data
were multiplied by a /3 shifted square sinebell function and zero-filled.
Base-line distortions were corrected with a fifth-order polynomial func-
tion. 1H-13C HSQC experiments were acquired using pulsed field gra-
dients for coherence selection (33). The chemical shift deviations of Ha
and Ca were calculated using random coil values reported in water (34).
The temperature gradients of the amide proton chemical shifts were
derived from a series of TOCSY spectra recorded at different tempera-
tures (from 283 to 303 K). The resonances assignments are listed in
Tables S1–S3 in the Supplemental Material.
Structure Calculation—Interproton distance restraints were derived
from the analysis of NOESY spectra. NOE cross-peaks were categorized
as strong, medium, and weak and converted into distance ranges of
0.18–0.28, 0.18–0.38, and 0.18–0.5 nm, accordingly. Pseudoatoms
were introduced for distances involving methyl protons and non-re-
solved methylene protons, and upper limits were corrected appropri-
ately (35). The  angle of L-amino acid residues was restrained to
negative values because all these residues did not exhibit strong intra-
residual dN NOEs. Structures were calculated using InsightII version
98.0 and Discover (Accelrys, San Diego, Inc.), running on SGI O2
R10000 workstations, and AMBER forcefield (36). The simulated an-
nealing protocol first comprised 15 ps of dynamics at 1000 K during
which the force constants of the distance and dihedral restraint terms
were gradually increased. The non-bond interaction, defined by a sim-
ple quartic repulsive potential, was slowly increased during the next 10
ps of dynamics. Finally, the structures were cooled from 1000 to 0 K
over 25 ps. The structures were then minimized by steepest descent and
conjugated gradient algorithms, using a Lennard-Jones potential for
the van der Waals interaction and a distance-dependent dielectric
screening of 4r for the electrostatic term.
Growth Factors and Peptides Synthesis
Recombinant human FGF-2 was kindly provided by Dr. Herve´ Prats
(INSERM U397, Toulouse, France) and stored in sterile, double-dis-
tilled water at 80 °C. Recombinant human VEGF165 was produced in
insect cells and purified as described elsewhere (37, 38). Human
VEGF165-encoding baculovirus was a kind gift of Dr. Jean Ploue¨t (In-
stitut de Pharmacologie et de Biologie Stucturale, UMR 5089, Toulouse,
France). CBO-P11 (cyclo-VEGI) (DFPQIMRIKPHQGQHIGE) and lin-
ear control CBO-P14 (PQIMRIKPHQGQHIGE) peptides were synthe-
sized by Fmoc/t-butyl batch solid phase synthesis on an Applied Bio-
systems 430A automated peptide synthesizer. For preparation of
protected peptide fragments, pre-loaded acid-labile 2-chlorotrityl resins
(H-His(Trt)2-ClTrt and H-Ile2-ClTrt resin) or HMPB-BHA resins based
on BHA polystyrene functionalized with Rink’s 4-hydroxymethyl-3-me-
thoxyphenoxybutanoic acid linker (Fmoc-Gly-HMPB-BHA resin) were
utilized. Subsequent Fmoc amino acids were coupled using a 4-fold
excess of amino acids activated as HOBt ester by means of DCC. The
crude linear protected peptides were analyzed by reverse phase high
pressure liquid chromatography on a Lichrosorb RP-18 column (Merck)
and purified on semi-preparative high pressure liquid chromatography.
Cyclization of the protected linear precursor (head-to-tail) was per-
formed by Fmoc/t-butyl/allyl strategy.2
Cell Culture
Bovine capillary endothelial (BCE) cells were a kind gift of Dr. Daniel
B. Rifkin (New York University Medical Center, New York). Bovine
aortic endothelial (BAE) cells were from Dr. Georg Breier (Department
of Molecular Biology, Max-Planck-Institut fu¨r physiologische und Kli-
nische Forschung, Bad Nauheim, Germany). All endothelial cells were
grown at 37 °C, 5% CO2 in DMEM containing 10% newborn calf serum,
2 mM L-glutamine, and 50 IU/ml penicillin, 50 IU/ml streptomycin
antibiotics and were used up to passage 25. BCE cells were grown in the
presence of 2 ng/ml FGF-2. CHO-VEGFR2 and CHO-VEGFR1 cells
were a kind gift of Dr. J. Ploue¨t (GDR CNRS 1927 “Angiogene`se,”
Toulouse, France). CHO-VEGFR2 and CHO-VEGFR1 were grown in
DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine, 1%
non-essential amino acids and antibiotics (Invitrogen). Balb3T3 were
grown in DMEM supplemented with 10% FBS, 2 mM L-glutamine, and
antibiotics. U87 human glioma cells (ATCC) were grown in minimum
Eagle’s -medium, 10% FBS, 2 mM L-glutamine, and antibiotics. GL261
murine glioblastoma cells (a gift from Dr. David Zagzag, New York
University, New York) were cultured in DMEM supplemented with
10% FBS, 2 mM L-glutamine, 1% non-essential amino acids, and
antibiotics.
Binding Assays
VEGF165 was labeled with Na
125I using IODO-GEN (Pierce) as cou-
pling agent according to the manufacturer’s instructions. BAE, CHO-
VEGFR2, and CHO-VEGFR1 cells were seeded at 2.5  105 density in
gelatin-coated 6-well plates and cultured in complete medium for 2
days. Cells were washed twice with ice-cold PBS and incubated with 10
ng/ml 125I-VEGF and peptides at indicated concentrations in binding
medium (DMEM; 20 mM Hepes, pH 7.4; 0.15% gelatin) on a shaker at
4 °C. After 2 h, cells were washed 3 times with PBS and solubilized by
the addition of 2% Triton, 10% glycerol, and 1 mg/ml bovine serum
albumin prior to -counting. Each condition was tested in duplicate and
repeated at least two times. Data are expressed as percentage of total
radioactivity.
Proliferation Assays
BCE and BAE cells were seeded in 24-well culture plates overnight
in 10% newborn calf serum at 7500 cells per well. Medium was changed
to 1% newborn calf serum, 10 ng/ml growth factor, and peptides at
indicated concentrations were added to duplicate wells. After 48 h,
medium was changed, and stimulation with growth factor and peptide
treatment were repeated. One day later, cells were counted on a Coulter
counter. Balb3T3 were seeded at a density of 10,000 cells/well in com-
plete medium. Medium was changed to 0.5% fetal calf serum and 20
ng/ml human recombinant PDGF-BB (Sigma), and peptides at indi-
cated concentrations were added to duplicate wells. Cells were counted
2 days later. U87 and GL261 cells were seeded at 10,000 cells/well in 1%
FBS, treated with peptides at the same concentrations as ECs, and
counted 72 h later. Each condition was tested in duplicate and repeated
at least two times.
ERK-1 (p44)/ERK-2 (p42) Phosphorylation Assay
BAE cells were plated in 35-mm plates. Subconfluent cultures were
serum-deprived for 24 h. Peptides were then added for 6 min in the
presence of 10 ng/ml VEGF165. Cells were scraped off the dish and lysed
for 10 min on ice in Nonidet P-40/SDS lysis buffer (50 mM Hepes, pH
7.4; 75 mM NaCl; 1 mM EDTA; 1% Nonidet P-40; 0.1% SDS) containing
a mixture of protease inhibitors. The insoluble material was removed by
centrifugation for 20 min at 12,000 g at 4 °C. The cleared supernatant
was stored at80 °C. Protein concentration was measured by using the
Bradford method (Bio-Rad). The cytoplasmic extracts were resolved by
SDS-PAGE on 12% gels under reducing conditions and electrotrans-
ferred onto a nitrocellulose membrane. The blocked membranes were
then incubated with primary antibodies (phospho-specific mitogen-ac-
tivated protein kinase p42/p44 or mitogen-activated protein kinase
2 S. Shinkaruk, L. Zilberberg, X. Canron, C. Chauseau, M. Bayle, B.
Desbas, A. Bikfalvi, and G. Deleris, manuscript in preparation.
Cyclic Vascular Endothelial Growth Inhibitor 35565
 at U











p42/p44 were obtained from New England Biolabs, Ozyme, France),
washed, and incubated with secondary horseradish peroxidase-conju-
gated mouse or rabbit antibodies (Dako SA, Trappes, France). Detection
of antibodies was performed using the ECLplus Western blot detection
system (Amersham Biosciences). Each condition was tested at least two
times.
Migration Assay
Migration test with BAE cells was performed using a method de-
scribed earlier (39). In brief, ECs were seeded in 350-mm culture plates
and were allowed to grow to confluence. Complete medium was replaced
with serum-free DMEM, and incubation was continued overnight. One
linear scar was drawn in the monolayer and divided into seven equal
fields. A set of digital photos was taken of each scar, and the denuded
area was marked using digital image analysis software (Lucia G, www.
lim.cz). The dishes were washed and incubated with fresh serum-free
medium containing 0.1% bovine serum albumin, 10 ng/ml VEGF165, and
peptides at indicated concentrations. After 16 h, cells were fixed in 1%
glutaraldehyde and counterstained (Giemsa), and a second set of photos
was taken. Photos were superposed, and endothelial cells having mi-
grated across the line drawn at the border of the scar in the first photo
set were counted. Each condition was tested in two independent exper-
iments. Means for all fields of each group were calculated; data are
expressed in percentage of the mean number of migrated cells over
VEGF165-induced cell migration.
CAM Assay
Fertilized chicken eggs (Gallus gallus) (E.A.R.L. Morizeau, Dangers,
France) were incubated at 37 °C and 80% humidified atmosphere. On
day 4 of development, a window was made in the eggshell and sealed
with Durapore® tape. On day 13, plastic rings (made from Nunc Ther-
manox® coverslips) were put on the CAM. 3 g of VEGF165 was pre-
mixed with 50 g of peptides or with the equivalent volume of sterile
water alone and deposed in the center of the plastic ring as described
previously (21). Treatment was repeated the following day. On day 17,
the CAMs were fixed in vivo with 4% paraformaldehyde for 30 min at
room temperature, and the area containing the ring was cut out for
further analysis. Photos of each CAM were taken under a stereomicro-
scope (Nikon SMZ800) using a digital camera (Nikon Coolpix 950). Two
observers scored the angiogenic response from 0 to 3 (0  none, 1 
medium, 2  medium/high, and 3  high). The angiogenic score was
indicated as the mean number from the two observers. Statistical
analysis was carried out using Student’s two-tailed t test. For confocal
studies, 6 CAM samples for each condition were processed. Each sample
was washed by incubation with 0.1% Triton in PBS. Fluorescein-Sam-
bucus nigra lectin (M0928 Vector Laboratories) at 40 g/ml was added,
and incubation was performed in 0.1% Triton/PBS for half an hour at
room temperature. Samples were washed 3 times with 0.1% Triton/
PBS, 3 times with PBS, and rinsed 3 times with water. The samples
were finally mounted and embedded with Antifading Prolong (Molecu-
lar Probes, Eugene, OR) and viewed by confocal fluorescent microscopy
at 600 magnification equipped with an anti-bleed through control
system based on sequential capture of the green signal (Nikon,
PCM2000).
Animal Experiments
Short-term Experiments—Groups of 10 6-week-old nude mice
(Charles River Italia, Italy) were implanted intracranially with 50,000
U87 glioma cells using an open window technique. For the syngeneic
model, groups of 10 6-week-old BALB/c mice (Charles River Italia) were
implanted intracranially with 50,000 GL261 glioma cells using the
same technique.
In a first group of experiments, 12 days after tumor cell injection,
groups of 10 nude or BALB/c mice each were treated intraperitoneally
with 2 mg/kg/day of cyclo-VEGI or saline in a single shot. Treatment
was continued for 28 days. Afterward, animals were sacrificed, and
their brains were removed, embedded in OCT, and stored at 70 °C.
In a second group of experiments, 12 days after tumor cell injection,
two groups of 10 nude mice each were implanted subcutaneously with
2004 Alzet osmotic minipumps. The pumps used in these experiments
afford a constant period of work of 28 days. In the first group, the pump
reservoir was filled with 0.45 mg (total amount) of the cyclo-VEGI, which
corresponds to 0.45 mg/kg/day. The second group of 10 animals was
implanted with pumps containing PBS, and a third additional group did
not receive any pumps. The last two groups served as the controls for the
experiment. Animals were sacrificed when signs of any distress were
evident and after 29 days from implantation of the pumps. Then the
brains were removed, embedded in OCT, and stored at 70 °C.
Long-term Experiments—For the long term experiments, groups of
10 nude mice each were implanted intracranially with 50,000 U87
glioblastoma cells using the same procedure described previously.
Twelve days after tumor cell injection, a first group of animals was
implanted subcutaneously with Alzet minipumps, and the reservoir
was filled with 0.45 mg (total amount) of cyclo-VEGI (0.45 mg/kg/day).
A second group of nude mice received subcutaneous minipumps con-
taining saline and served as a control. Twenty-eight days later, the
pump was changed with a new one containing the same amount of the
inhibitor, in order to afford a 58-day period of treatment. Animals were
carefully monitored for the occurrence of any side effects and immedi-
ately sacrificed at the occurrence of any neurological deficits. Seventy
days after tumor cell implantation, all the remaining animals were
sacrificed. All animal experiments were repeated at least two times.
All brains were fixed in 5% paraformaldehyde in PBS for 24 h at 4 °C,
dehydrated in 30% sucrose in PBS for 24 h at 4 °C, embedded in OCT,
and stored at 70 °C. The brains were then sectioned, and a portion of
them submitted to routine histological examination with hematoxylin
and eosin staining. Tumor volume was calculated and expressed as a
mean  S.E. Tumor volume was estimated using the formula for ellip-
soid (width2  length)/2. The remaining slides were used for the immu-
nohistochemistry analysis as described below. Kaplan-Meyer survival
curves were statistically analyzed using repeated measures analysis of
variance.
Immunohistochemistry
Immunohistochemistry was performed on 5-m sections. Immuno-
histochemistry on 5-m sections was carried using the Vectastain Elite
kit (Vector Laboratories). Primary antibodies include anti-CD31 (1:100
dilution, BD Biosciences) and anti-Ki-67 (1:100 dilution, Dako). Detec-
tion was carried out using DAB chromogen. Sections were counter-
stained with hematoxylin. Negative control slides were obtained by
omitting the primary antibody. Ki-67 staining was quantified by count-
ing the number of positively stained cells of 100 nuclei in 20 randomly
chosen fields (40, 41). Microvessel count and density were scored as
reported previously (40, 41). Apoptotic cells were detected with Apop-
TagTM plus kit (Genenco International, New York) with 1% methyl
green as a counterstain. Apoptosis and proliferative indices were quan-
tified by determining the percentage of positively stained cells for all
nuclei in 20 randomly chosen fields per section at 200 magnification
(40).
RESULTS
Secondary and Three-dimensional Structure of
Cyclo-VEGI
Secondary Structure—Standard NMRmethodology was used
to obtain sequence-specific assignments of proton resonances in
water and in TFE/water mixtures at two different ratios, 15:85
or 30:70 (v/v). TOCSY spectra were used to identify spin sys-
tems, and NOESY spectra were used to obtain inter residue
connectivities (42). The 13C resonances of C carbons were
assigned from 13C-1H HSQC spectra. Weak additional reso-
nances could be observed in the NMR spectra recorded in water
and also in TFE/water mixtures, albeit to a lesser extent. In the
absence of chemical heterogeneity, a likely explanation of the
observed chemical shift heterogeneity would be cis-trans isom-
erism of peptide bonds preceding proline. The major form cor-
responds to a trans conformation of the peptide bonds preced-
ing the two Pro residues, as evidenced by the observation of
strong  (i  1,i) sequential NOEs. The proportion of minor
forms was too weak to give rise to NOE cross-peaks. However,
the presence of alternative spin systems of Gln/Glu, Phe, His,
and Lys in TOCSY spectra, i.e. amino acids around Pro resi-
dues, suggests that both D-Phe1–Pro2 and Lys8–Pro9 peptide
bonds are likely to isomerize. The lower proportion of minor
species in mixtures of TFE/water indicates that the stabiliza-
tion of folded structures (see below) decreases the amount of cis
isomers, as observed for cyclic gramicidin S.
The chemical shift deviations (CSDs) of H and C reso-
nances, calculated as the difference between observed chemical
Cyclic Vascular Endothelial Growth Inhibitor35566
 at U











shifts and corresponding random coil values, carry information
about the secondary structure (43). A stretch of residues exhib-
iting upfield shifts of H protons and downfield shifts of C
carbons is characteristic of a helix, whereas the observation of
downfield shifts of H and upfield shifts of C indicates the
presence of -sheet structures. Fig. 1 shows the H and C
CSDs in water and in TFE/water mixtures. The peptide in
water displays very weak CSDs along its whole sequence, in-
dicating that it is largely unstructured in aqueous solution. The
addition of TFE (from 15 to 30%) progressively induces an
upfield shift of H and a downfield shift of C resonances for
residues 1–6, supporting the formation of a helical structure.
Because the corresponding H CSDs are slightly negative in
water, this suggests that the 1–6 segment has a small helical
propensity in water and that helical conformations explored in
this region are stabilized by the addition of TFE. Strong upfield
shifts of amide protons chemical shifts are also induced by the
addition of TFE for residues 3–8. Interestingly, these varia-
tions are opposite to those observed for cyclic gramicidin S
under the same conditions and are correlated to the formation
of a -sheet structure. Furthermore, residues 3–8 exhibit weak
temperature gradients of their amide proton chemical shifts
(NH/T). Altogether, these chemical shift data are consistent
with the formation of a helical structure in segment 1–8. No
significant CSD variations could be observed in the other parts
of the sequence, suggesting that the peptide remains unstruc-
tured, apart from the 1–8 region.
Three-dimensional Structure—The cyclic peptide shows few
NOEs in water, besides intraresidual and sequential connec-
tivities. In contrast, the peptide in 30% TFE exhibits NOEs
characteristic of helical structure in segment 1–8, including
strong dNN (i,i  1) and medium dN (i,i  1) sequential
connectivities, together with several dN (i,i 2), dN (i,i 3),
and dN (i,i 4) medium range connectivities. The structure of
the cyclic peptide in 30% TFE was calculated by restrained
molecular dynamics, using a set of 17 intraresidual, 63 sequen-
tial, and 20 medium range distance restraints. The best 20
calculated structures are shown in Fig. 2. They have low ener-
gies and few distance violations, indicating that they are in
good agreement with NMR experimental restraints. The over-
all structure of the cyclic peptide is poorly defined, as evidenced
by the large root mean square deviation of backbone atoms (3.4
Å). However, the superimposition of structures using backbone
atoms of residues 1–8 or 1–6 shows that the backbone is better
defined in this region, with corresponding root mean square
deviations of 1.6 and 1.1 Å, respectively. Segment 1–8 adopts a
helical conformation. Unexpectedly, residues D-Phe1–Pro2 do
not form a type II -turn but are rather part of the helical 1–8
segment, as shown by medium range correlations between
D-Phe1–Ile4 and Pro2–Met5. Similarly, residues Pro9–His10 do
not form a stable -turn. The conformations of other residues
are not well defined but are not completely random coil due to
the cyclic topological constraint.
Inhibition of VEGF Binding to Its Receptors
We first looked at the ability of cyclo-VEGI to interfere with
binding of 125I-labeled VEGF165 to Chinese hamster ovary
(CHO) cells expressing VEGFR2. Cyclo-VEGI inhibited 125I-
labeled VEGF165 binding to VEGFR2 in a dose-dependent man-
ner (Fig. 3A) with a half-maximal inhibition (IC50) of 1.3 M.
The linear control peptide P14 with the same amino acid se-
quence as cyclo-VEGI did not compete for receptor binding even
at the highest concentration tested (Fig. 3A). To investigate
whether cyclo-VEGI inhibits binding of VEGF165 to VEGFR2
specifically, we tested the effect of cyclo-VEGI on the binding of
125I-labeled VEGF165 to CHO cells expressing VEGFR1. Inter-
estingly cyclo-VEGI also inhibited binding of VEGF to VEGFR1
(IC50 value of 0.7 M, Fig. 3B). We next evaluated its effect on
125I-labeled VEGF165 binding to high affinity VEGF receptors
FIG. 1. H (A), C (B), and HN (C) CSDs of cyclo-VEGI peptide
in water and TFE/water mixtures.
FIG. 2. Backbone superimposition of the best 20 structures
calculated in 30% TFE. A, superimposition of residues 1–17. B, su-
perimposition of residues 1–8, showing the helical domain.
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in BAE cells. As shown in Fig. 3C, cyclo-VEGI effectively in-
hibits the binding of 125I-labeled VEGF165 to high affinity re-
ceptors with an IC50 of 12 M. Linear control P14 at the highest
concentration tested (50 M) had no effect (Fig. 3C).
Inhibition of the Proliferation of Endothelial Cells but
Not of Glioma Cells
We next investigated whether cyclo-VEGI inhibits VEGF-
induced proliferation of BAE cells. When BAE cells were stim-
ulated by 10 ng/ml of VEGF165, cyclo-VEGI showed a dose-de-
pendent inhibitory effect with an IC50 of 5.8 M, whereas the
linear control P14 had no effect at the highest concentration
tested (100 M) (Fig. 4A).
VEGF is a member of the cystine-knot family of growth
factors, with the highest sequence identity and structural sim-
ilarity to PDGF-BB (44, 45). Moreover, endothelial cell prolif-
eration is induced by FGF-2 (46). Thus, to investigate whether
the effect of cyclo-VEGI on endothelial cells proliferation was
specific for VEGF165, we tested the activity of cyclo-VEGI on
PDGF- or FGF-induced cell proliferation. When Balb3T3 cells
were stimulated with 20 ng/ml PDGF-BB, cyclo-VEGI did not
show any effect even at the highest concentration tested (50
M) (Fig. 4B). Surprisingly, cyclo-VEGI decreased FGF-induced
BCE proliferation, however three times less potently (IC50 of 18
FIG. 3. Inhibition of 125I-VEGF165 binding to CHO-VEGFR2 (A),
CHO-VEGFR1 (B), and BAE (C) cells by cyclo-VEGI. CHO-
VEGFR2, CHO-VEGFR1, and BAE cells were incubated with 10 ng/ml
125I-VEGF165 and peptides at indicated concentrations. Cyclo-VEGI
inhibited VEGF165 binding in a dose-dependent manner, whereas the
control peptide P14 did not, even at 100 M on CHO-VEGFR2 cells (A),
or 50 M on CHO-VEGFR1 (B), and BAE (C) cells. The half-maximal
inhibition (IC50) values were 1.3, 0.7, and 12 M for CHO-VEGFR2,
CHO-VEGFR1, and BAE cells, respectively. Data represent means 
S.D. of duplicate experiments. The figure depicts a representative ex-
periment from two independent experiments.
FIG. 4. Effect of cyclo-VEGI on cell proliferation. Proliferation
was stimulated with 10 ng/ml VEGF165 using BAE cells (A), 10 ng/ml
FGF-2 using BCE cells (B), and 20 ng/ml PDGF-BB using Balb3T3 cells
(B) and 1% serum using U87 and GL261 cells (C). A, cyclo-VEGI
inhibited BAE cell proliferation in a concentration-dependent manner
(IC50 of 5.8 M). 100% inhibition of proliferation was achieved with 20
M cyclo-VEGI. The linear control P14 did not show any effect. B,
cyclo-VEGI inhibited FGF-2-induced proliferation of BCE cells in a
dose-dependent manner with an IC50 of 18 M. Peptide P14 had no
effect. Cyclo-VEGI did not show any effect at all concentrations tested
on PDGF-BB-induced Balb3T3. C, cyclo-VEGI did not show any effect at
all concentrations tested on U87 and GL261 cells proliferation. Dose
dependence experiments were performed in duplicates in two independ-
ent experiments; data of one experiment are shown. D, inhibition of
VEGF-stimulated MAP kinase phosphorylation. Serum-deprived bo-
vine aortic endothelial cells (1st lane) were stimulated with 10 ng/ml
VEGF165 (2nd lane) in the presence of 20 M cyclo-VEGI (3rd lane), or
20 M of linear control P14 (4th lane). Cell lysate blot was probed with
phosphospecific ERK1 and ERK2 antibodies, and the total amount of
MAPs protein loading was assessed by probing with MAP antibodies.
Blots depict a representative experiment from two independent
experiments.
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M in comparison to 5.8 M for VEGF-induced endothelial cell
proliferation) (Fig. 4B). Proliferation of two glioma cell lines,
human U87 and mouse GL261 cells, was not inhibited by
cyclo-VEGI peptides at all the concentrations tested (Fig. 4C).
Inhibition of VEG165 Signal Transduction
We next investigated the effect of cyclo-VEGI on ERK1 and
ERK2 phosphorylation. As expected, activation of VEGFR2
with 10 ng/ml VEGF165 in BAE cells induced a strong phospho-
rylation of ERK1 and ERK2 (Fig. 4D, 2nd lane). Cyclo-VEGI, at
20 M, completely suppressed VEGF-induced ERK1 and ERK2
phosphorylation (Fig. 4D, 3rd lane). The linear control P14 did
not show any inhibitory effect on VEGF165-induced phospho-
rylation of ERK1 and ERK2 (Fig. 4D, 4th lane). Similar results
were also observed on human umbilical vein endothelial cells
stimulated with 10 ng/ml of VEGF165 (data not shown).
Inhibition of Endothelial Cell Migration
We then investigated whether endothelial cell motility, an
important pre-requisite for angiogenesis, was affected by cyclo-
VEGI. The wounding assay was used to determine the effect of
cyclo-VEGI on VEGF-induced bovine aortic endothelial cells
migration in vitro. In the absence of VEGF, some random
background migration occurred (Fig. 5A). When stimulated
with VEGF165, an increased number of BAE cells migrated into
the denuded scar area (Fig. 5B). Migration was not affected
when the linear control peptide (P14) was added (Fig. 5, D and
E). On the contrary, cyclo-VEGI inhibited VEGF-induced mi-
gration of endothelial cells in a dose-dependent manner with an
IC50 of 8.2 M (Fig. 5, C and E). Inhibition of migration of the
endothelial cells below base-line levels was also observed (Fig.
5E).
Inhibition of VEGF-induced Angiogenesis on the CAM
Peptides were tested in the differentiated CAM assay, where
capillary angiogenesis is induced by VEGF165 (21). For this
experiment, a plastic ring is filled in the center with 3 g of
VEGF165 alone or with VEGF165 plus either the vehicle alone
(water), 50 g of cyclo-VEGI, or 50 g of the control peptide
P14. Recombinant human VEGF165 alone induced significant
angiogenesis (Fig. 6, B and I). Some stimulation is also present
around the site of application because of diffusion of the growth
factor. Vehicle alone (water) in the plastic ring had no effect
(Fig. 6, A and I). When premixed with VEGF165 and deposed on
the CAM, a clear anti-angiogenic effect of cyclo-VEGI was
visible inside the ring (Fig. 6, C and I). The linear control P14
did not inhibit VEGF-induced capillary growth in the CAM
(Fig. 6, D and I). 50 g of cyclo-VEGI applied alone on the CAM
without VEGF165 did not show any effect or toxicity (data not
shown).
The capillary structure in the stroma was also examined by
immunohistology and confocal microscopy. Vessels were visu-
alized by staining endothelial cells with fluorescein isothiocya-
nate (FITC) conjugated to S. nigra lectin. This lectin interacts
preferentially to sialic acid attached to terminal galactose by
-2,6-link and was shown to bind endothelial cells in the CAM.
The extensive characterization of the CAM vasculature using
this method will be described elsewhere.3 VEGF165 induced a
strong increase in vessel density, a reduction of the inter-
capillary space, and structures suggestive of ongoing fusion
events between small vessels (Fig. 6F). These chaotic vascular
structures were not present when cyclo-VEGI was added to-
gether with VEGF165 in the plastic ring (Fig. 6G). However,
some neovessels remained, as evidenced by a slightly higher
microvessel density compared with control CAM treated with
water alone (Fig. 6, G and E). CAMs treated with control
peptide P14 with VEGF165 had a similar morphology than
CAMs treated with VEGF165 alone (Fig. 6H).
Inhibition of Glioma Growth in Vivo
The ability of cyclo-VEGI to reduce glioma growth in vivo
was initially investigated by short term studies. In these ex-
periments, nude mice implanted intracranially with human
glioblastoma cells were treated intraperitoneally with 2 mg/kg/
day of cyclo-VEGI. Treatment was started 12 days after tumor
cell implantation in order to treat well established tumors.
Twenty eight days later, the treatment was stopped, and the
animals were sacrificed. Histological analysis of the brains
from treated and untreated animals showed that treatment
with cyclo-VEGI was associated with a 70% reduction of U87
tumor growth (Fig. 7A, lower panel). A similar significant in-
hibition (78%) was observed in immunocompetent BALB/c mice
implanted with GL261 murine glioblastoma cells (Fig. 7A, top
panel).
In a second set of experiments we investigated the ability of
cyclo-VEGI to reduce U87 glioma growth when administered
continuously and systemically by subcutaneous minipumps in
nude mice. In these experiments, the pump reservoirs were
filled with 0.45 mg/kg/day of the inhibitor. Analysis of tumor
3 M. Hagedorn, M. Balke, A. Schmidt, W. Bloch, H. Kurz, S. Javerzat,
B. Rousseau, J. Wieting, and A. Bikfalvi, submitted for publication.
FIG. 5. Migration of BAE cells in the presence of VEGF165 and
different concentrations of cyclo-VEGI. BAE migration was stim-
ulated with 10 ng/ml VEGF165. A, after 16 h in serum-free medium,
some random cell migration occurred. B, VEGF165 induces cell migra-
tion into the denuded area of the scar. At 50 M, linear control P14 (D)
had no effects, whereas cyclo-VEGI (C) completely abolished VEGF165-
induced endothelial cell migration. E, cyclo-VEGI reduces migration of
the endothelial cells in a dose-dependent manner. Horizontal line at 0
indicates conditions where 100% inhibition of VEGF-induced migration
is reached. Data are expressed in percentage of the mean number of
migrated cells of seven fields over VEGF165-induced cells migration.
Dose dependence experiments were performed in two independent ex-
periments; data of one experiment are shown.
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volumes showed that continuous systemic administration of
peptide cyclo-VEGI resulted in a 72% inhibition of intracranial
glioma growth (Fig. 7B, top panel).
The same experimental design was used to perform long-
term experiments. In these studies, the pump reservoirs were
changed with a new one containing the same amount of the
FIG. 6. Anti-angiogenic activity of
cyclo-VEGI in the chick CAM assay.
A–D, images of representative CAMs for
each condition are shown (A, water, n 
12. B, VEGF165, n  27. C, cyclo-VEGI,
n  40. D, P14, n  22). E–H, confocal
observation of representative CAMs for
each condition are shown (white bar
equals 50 m for all photos). I, angiogenic
score was determined by scoring from 0 to
3 the appearance of the brush-like capil-
lary formation by two independent ob-
servers. Sterile water alone did not inter-
fere with CAM vasculature (A, E, and I).
VEGF165 induced a strong brush-like cap-
illary formation (B, F, and I). Control pep-
tide P14 was not able to impair growth of
new capillaries (D, H, and I). Neoangio-
genesis was significantly reduced nearly
to control level in the CAMs that received
VEGF165 plus 50 g of cyclo-VEGI (C, G,
and I). Statistical analysis (Student’s two-
tailed t test) proved the difference be-
tween VEGF165 and cyclo-VEGI to be sig-
nificant (**, p  0.001, I).
FIG. 7. Cyclo-VEGI induces regression of gliomas in nude and syngeneic mice. A, cyclo-VEGI reduced significantly the growth of human
U87 glioma xenografts in nude mice (lower panel, **, p  0.001) and GL261 glioma in immunocompetent BALB/c mice (top panel, **, p  0.001).
Mice were treated intraperitoneally with 2 mg/kg/day cyclo-VEGI. B, U87 glioma bearing-mice were treated with cyclo-VEGI administrated
continuously and systemically by subcutaneous minipumps, and the reservoir was filled with 0.45 mg/kg/day cyclo-VEGI. In short-term experi-
ments, the tumors of the mice treated with cyclo-VEGI were significantly smaller than those of the control mice (top panel, 72% inhibition and *,
p  0.05). In long-term studies, tumor-bearing mice treated with cyclo-VEGI survived significantly longer than those in the control group (75 and
32 days of 50% survival respectively, lower panel). C, CD31 staining of tumor samples revealed a decrease in the numbers of vessels in
the cyclo-VEGI-treated group compared with PBS-treated tumors (top panel and **, p  0.001). Increased apoptotic indices in samples from the
cyclo-VEGI-treated tumors were observed compared with PBS-treated mice (middle panel and **, p  0,001). Ki-67 staining revealed that
cyclo-VEGI has no effect on tumor cell proliferation compared with PBS-treated tumors (lower panel).
Cyclic Vascular Endothelial Growth Inhibitor35570
 at U











inhibitor 28 days after implantation. Animals belonging to the
control group showed a 50% survival of 32 days. Animals
treated with cyclo-VEGI had a 50% survival of 75 days. No side
effects were registered during the entire duration of the treat-
ment (Fig. 7B, lower panel).
Histological Analysis
We next performed histological analysis of U87 glioma sec-
tions from the short-term and long-term experiments (using
the subcutaneous minipumps). To quantify angiogenesis in
these tumors, we stained endothelial cells for the expression of
CD31. Treatment of U87 tumors with cyclo-VEGI reduced mi-
crovessel density by 68 and 62% when compared with PBS-
treated controls for short-term and long-term experiments, re-
spectively (Fig. 7C, top panel). A more detailed analysis
revealed that, in control tumors, 55% capillary-like structures,
35% teleangiectatic or dilated vessels, and 10% glomeruloid
structures were present. In cyclo-VEGI-treated tumors, 85%
capillary structures, 15% teleangiectatic or dilated vessels, and
no glomeruloid structures were observed. This indicates that
vessels tends to be normalized by cyclo-VEGI treatment. Ap-
optotic indices quantified in situ by labeling fragmented DNA
using the terminal deoxynucleotidyltransferase-mediated nick
end labeling method were increased in tumors treated with
cyclo-VEGI compared with PBS-treated controls (Fig. 7C, mid-
dle panel). An examination of proliferating cells within the
tumor using Ki-67 nuclear antigen staining revealed no differ-
ences in the proliferating indices between PBS-treated controls
and any cyclo-VEGI-treated groups (Fig. 7C, lower panel).
DISCUSSION
Structural and mutagenesis studies have shown that the
residues within the amino acid sequence 79–93 of VEGF are
involved in its interaction with VEGFR2 and that Arg82, Lys84,
and His86 are key residues. The x-ray structure of VEGF-A
revealed that this sequence is located within a -sheet struc-
ture formed by two anti-parallel strands (5 and 6) and con-
nected by a type II -turn (27–29, 47). We designed linear and
cyclic peptides based on this sequence and tested them for
inhibition of VEGF165 binding to VEGFR2. It appears that a
17-amino acid cyclic peptide (CBO-P11), herein designated cy-
clo-VEGI, inhibits very efficiently the binding of VEGF to its
receptor VEGFR2.2 In this article, we undertook a series of
systematic studies to determine the structural and biological
properties of this peptide.
In aqueous solution, the cyclic peptide presents a weak pro-
pensity to adopt a helix structure in the 1–8 domain. The
addition of TFE stabilizes helical conformations in this region,
without any noticeable effect on the structure of the other parts
of this peptide. TFE is known to strengthen intramolecular
hydrogen bonds in peptides. The stabilization of the secondary
structure by TFE has been observed for cyclic analogs of gram-
icidin S containing 4n  2 residues, but intramolecular hydro-
gen bonding occurs between two strands in this latter case,
resulting in the stabilization of -sheet structures (48). The
property of this cyclic peptide to adopt helical conformations
was largely unexpected because mostly -sheet structures or
random coil conformations have been observed for macrocyclic
peptides (49).
Pro has two opposite roles as inducer of helical structure
when located at the N terminus or helix breaker or bender
when found in the middle of a helical domain. In this cyclic
peptide, Pro2 and Pro9 have these two opposite effects. Indeed,
Pro2 induces the formation of helix, whereas Pro9 breaks the
1–8 helical domain. The heterochiral D-Phe-Pro sequence is
known to adopt either a type II -turn or a -turn in small
cyclic peptides. In this macrocyclic peptide, Pro2 is not part of a
type II -turn and initiates helix formation. Thus, despite the
presence of a motif known to stabilize a type II -turn in
-hairpins, the peptide does not adopt a -sheet structure.
However, it is not in a random coil state, because region 1–8 of
the peptide explores helical conformations. This topology could
open new possibilities in the design of scaffolds for protein
engineering, because further chemical modifications, such as
Cmethylation, could be used to stabilize the -helical domain.
The residues Arg82, Lys84, and His86 localized in the -hairpin
79–93 of VEGF are implicated in the binding to the VEGFR2
receptor. In this VEGF cyclic peptide, they are found at the end
of the helical domain. Their side chains are not well defined,
and it is likely that they retain enough conformational flexibil-
ity in the cyclic peptide to explore the orientation required for
binding to the VEGF receptors and to prevent VEGF binding.
Although VEGFR1 binds VEGF with 50-fold higher affinity
than VEGFR2, most of the VEGF angiogenic properties like
mitogenicity and migration of endothelial cells are mediated by
interaction with VEGFR2 (6, 50). Thus, our initial goal was to
design peptides that specifically interfere with binding of
VEGF to its receptor VEGFR2. Indeed, cyclo-VEGI did inter-
fere with VEGF165 binding on CHO-VEGFR2 in a dose-depend-
ent manner. The linear control peptide P14 with the same
amino acid sequence as cyclo-VEGI did not compete for recep-
tor binding even at the highest concentration tested (Fig. 3A).
This indicates that the inhibitory effect of cyclo-VEGI is struc-
ture-dependent. This result is in agreement with the results of
other groups who showed that residues 82–90 in the loop be-
tween -strands 5 and 6 of VEGF are critical for binding to and
activation of VEGFR2 (51, 52). This loop is part of the cyclo-
VEGI peptide we have designed. Surprisingly, our peptide also
inhibited the binding of VEGF165 to VEGFR1. One possible
explanation for this finding might be that the receptor binding
domain determinants of VEGF165 for VEGFR1 and VEGFR2
share similar residues. Indeed, crystallographic studies of
VEGF bound to the second Ig-like domain of VEGFR1 and
mutagenesis analysis of the binding surface of VEGF for
VEGFR2 revealed that some but not all residues in this loop
domain are important for the binding to both receptors,
VEGFR1 and VEGFR2 (27, 28).
Treatment of BAE cells with micromolar concentration of
cyclo-VEGI strongly inhibited VEGF165-induced cell prolifera-
tion. Although selectivity was observed for inhibition of VEGF-
induced proliferation of endothelial cells in comparison to the
structurally related growth factor PDGF-BB, cyclo-VEGI was
also found to impair FGF-2-induced endothelial cell prolifera-
tion. Nevertheless, the activity of cyclo-VEGI appears to be
severalfold lower toward FGF-2 than toward VEGF. This effect
of cyclo-VEGI on FGF-2-induced proliferation was rather un-
expected but may constitute an advantage for several reasons.
First, it has been shown previously that FGF-2 can induce
production of VEGF via an autocrine feedback loop and that
both growth factors can synergize with respect to their ability
to induce angiogenesis (53, 54). Second, this might prove ben-
eficial in vivo, because tumor cells can produce both VEGF and
FGF-2 and their inhibition has a synergistic effect in the im-
pairment of tumor growth (55, 56). This is also illustrated by
the observation that a modified peptide derived from platelet
factor-4, which inhibits FGF-2 and VEGF165-induced endothe-
lial proliferation, had a strong inhibitory effect on human in-
tracranial established glioma growth (21). The reasons for the
effect of cyclo-VEGI on FGF-2 activity are not clearly under-
stood. HSPGs are molecules found on the cell surface of almost
all mammalian cells and have been shown to modulate the
biological activity of growth factors (57). FGF-2 and VEGF165
function in concert with cell surface-bound HSPGs to promote
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binding to their specific receptors and to induce their biological
responses (58). We cannot rule out the possibility for cyclo-
VEGI to bind to the cell surface heparan sulfate proteoglycans
(HSPGs) because of its basic residues, thus preventing the
binding of VEGF165 and FGF-2 to their receptors and subse-
quently inhibiting proliferation of endothelial cells. However,
the linear control peptide P14, which has the same sequence as
cyclo-VEGI, does not have any antagonist effect on FGF-2 or
VEGF165-induced proliferation even at the highest dose of 100
M. This finding suggests that cyclo-VEGI inhibits FGF-2-in-
duced endothelial cell proliferation by another mechanism,
probably involving specific structural properties of this cyclic
peptide. Preliminary experiments indicate that cyclo-VEGI
also impairs FGF-2 binding to endothelial cells, although at
higher cyclo-VEGI concentrations. Further studies are under-
way to solve this issue.
To substantiate further the antagonist activity of cyclo-
VEGI, we tested its activity on VEGF-induced signaling and
migration. MAP kinases play a central role in controlling
growth signals from growth factor receptor tyrosine kinases
such as VEGFR2 (59). In agreement with the effect of cyclo-
VEGI on VEGF-induced endothelial cell proliferation, we also
observed an inhibition of MAP kinase activation by cyclo-VEGI
in endothelial cells upon VEGF stimulation. Migration of en-
dothelial cells, an important pre-requisite for angiogenesis,
was also affected by cyclo-VEGI in a dose-dependent manner.
Cyclo-VEGI inhibited EC migration below 0% serum control
levels which suggests that residual VEGF was still present in
the media. This may be due to the presence of residual
VEGF165 attached to HSPGs on endothelial cells or of VEGF
produced by endothelial cells themselves (60, 61).
We next tested effects of cyclo-VEGI for its ability to interfere
with VEGF165-induced angiogenesis on the differentiated day
13 CAM (62). The typical brush-like formation of capillaries in
the stroma of the CAM induced by human recombinant
VEGF165 is strongly reduced by cyclo-VEGI peptides at 50 g
and not by linear control peptide P14. Cyclic peptide antago-
nists for V3 integrin showed strong anti-angiogenic effects in
the day 10 CAM at 300 g. Angiogenesis was also induced by
VEGF at lower doses than in our assay (1 versus 6 g) (63).
These comparisons indicate that cyclo-VEGI inhibits VEGF-
induced angiogenesis in vivo in a very efficient way.
Gliomas constitute the most frequent class of primary brain
tumors and are among the most malignant cancers, often re-
sulting in the death of affected patients within months (64). In
our model, established human intracranial glioma in nude mice
decreased significantly by 	70% in size when treated with
cyclo-VEGI in short and long term experiments. Moreover tu-
mor-bearing mice treated with cyclo-VEGI lived significantly
longer than those in the control group. Highly vascularized
brain tumors such as gliomas produce high levels of VEGF in
culture (56, 65). The decreased number of vessels for the cyclo-
VEGI-treated tumors is consistent with a direct inhibition of
VEGF signaling (as observed in our in vitro experiments) which
in turn impairs tumor growth. This is also in agreement with
an indirect (i.e. anti-angiogenic) antitumor effect rather than a
direct antiproliferative effect on the tumor cells as evidenced by
the absence of effect of cyclo-VEGI on the proliferation of tumor
cells in vitro and in vivo. Histological analysis of cyclo-VEGI-
treated gliomas showed characteristic findings observed in tu-
mors treated with other potent anti-angiogenic compounds like
endostatin and angiostatin. Although the proliferation index
remained unchanged in tumor tissue irrespective of treatment,
cyclo-VEGI decreased microvessel density which was accompa-
nied by an increase in the apoptotic index as observed previ-
ously for other angiogenesis inhibitors (66, 67).
Taken together, these results indicate that cyclo-VEGI ex-
hibits unique structural features and inhibits angiogenesis and
tumor development in vivo. Furthermore, its inhibitor activity
affects multiple angiogenesis pathways. Cyclo-VEGI is a prom-
ising candidate for the development of new cyclic angiogenesis
inhibitor molecules useful for the treatment of cancer or other
angiogenesis-related diseases.
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